Oncolytics Biotech(R) Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, under its Clinical Trials Agreement with Oncolytics. Oncolytics will provide clinical supplies of REOLYSIN for this study. The Study Chair will be Dr. David E. Cohn of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Tethys Petroleum Limited: Kazakhstan Drilling Update

Tethys Petroleum Limited ("Tethys" or the "Company") (TSX: TPL) today gave a brief update on its operations in Kazakhstan focused on its oil exploration and appraisal program.

The AKD03 (Dione) exploration well is currently at a depth of 2,823 metres (in what is interpreted to be the middle Jurassic sequence) and casing has been run. Hydrocarbons have been indicated from drilling and log data in three zones and a testing programme is planned for the near future. Once this testing programme has been carried out the well will be drilled deeper into the Triassic sequence.

The G6RE (Dodone) well has now been drilled to a depth of 2,835 metres in order to test a deeper potential oil bearing zone identified from the wireline logs in the original G6 hole. The hole is currently being prepared to run casing but differential sticking in the bottom section probably caused by higher formation pressures and permeable zones has slowed down the process. Once casing has been run, preparations for testing can commence.

Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

The article offers data demonstrating that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol^®) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.

Sycamore Networks, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results

Sycamore Networks, Inc. (NASDAQ: SCMR), today reported its results for the fourth quarter and fiscal year ended July 31, 2010. Revenue for the fourth quarter of fiscal 2010 was $22.2 million, compared with $17.2 million for the fourth quarter of fiscal 2009. Revenue for fiscal 2010 was $68.6 million compared to $67.4 million in fiscal 2009.

Net income for the fourth quarter of fiscal 2010, on a generally accepted accounting principles (“GAAP”) basis, was $0.5 million, or $0.02 per diluted share, compared with a GAAP net loss of $34.9 million, or $1.23 per share for the fourth quarter of fiscal 2009. Net loss for fiscal 2010, on a GAAP basis, was $14.8 million, or $0.52 per share, compared with a GAAP net loss of $53.6 million, or $1.89 per share for fiscal 2009.